This week, we debunked pharma’s lies about how drug pricing reforms will hinder innovation and patient access to medications; highlighted taxpayers’ critical role in funding the research and development of COVID-19 vaccines; and explained why we must lower drug prices to lower out-of-pocket costs. See our full campaign to set the record straight on the comprehensive reforms in Congress here

Today, we’ll lay out the strong bipartisan support for drug pricing reform and why the Senate must pass these reforms now.

Big Pharma’s Lie: Big Pharma’s Lie: The package of drug pricing reforms is an unpopular partisan plan pushed by Democratic congressional leaders.

✅ The Truth: Drug pricing reform has overwhelming bipartisan support across the country.

Watch here.

Summary:

Americans – Republicans, Democrats, and independents alike – overwhelmingly support action to lower drug prices. Nine in 10 Americans support allowing Medicare to negotiate prices, limiting annual drug price hikes to the rate of inflation, and capping out-of-pocket costs for insulin at $35 a month. Medicare negotiation is the most popular priority in the president’s economic plan. Nearly 90 percent of voters said drug pricing is an important issue heading into the November midterm elections, and 3 in 4 said a failure by Congress to lower drug prices will affect their vote. In February, over 90 groups representing patients, seniors, consumers, unions, employers, physicians, and disease advocacy groups signed a letter urging the Senate to pass the drug pricing reforms in a reconciliation package. There is a clear path forward for Congress to pass the drug pricing reforms and help patients and taxpayers now.

Patient Perspective:

“While our country wrestles with deep divisions on so many issues, the overwhelming popularity of prescription drug pricing reforms before the Senate right now is striking. Despite Big Pharma’s record spending on lobbying and dark money campaigns to block the drug pricing reforms, patients know the provisions will allow for the innovation we need at prices we can afford, increase access to drugs, continue funding for COVID-19 vaccine development, and save lives. Americans are depending on Congress to fulfill its promise and pass comprehensive drug pricing reforms now,” says David Mitchell, a patient with incurable blood cancer whose drugs carry a list price of more than $900,000 per year and founder of Patients For Affordable Drugs Now.

###